Therapeutic Biologics

In veterinary and human medicine, novel products are currently being developed to harness nonspecific and select immune responses intended to support treatment of serious, systemic disorders. Although labeled as biologics, these immune therapeutic agents do not act in the same manner as conventional vaccines (also called biologics). Instead, these products are specifically intended to elicit an immune response that may alter the course of the disease (e.g., cancer) or modify the patient’s response to an immunologically mediated disorder (e.g., atopic dermatitis, osteoarthritis).

The following table includes only those products that have been licensed (fully or conditionally) by the U.S. Department of Agriculture and are available in the United States. This information is included in the AAHA Canine Vaccination Guidelines to identify immune therapies licensed for use in dogs. Included is a brief description of indications for use, availability (i.e., some products are only available through specialists, e.g., oncologists), proposed mechanism(s) of action, and general comments. This table is NOT intended to serve as a comprehensive guideline for the administration of any product to an individual patient.

This table will be updated as new products are licensed and become available for use in veterinary medicine.

Canine Oral Melanoma
Canine B-cell Lymphoma
Canine Atopic Dermatitis Immunotherapeutic
Lymphocyte T-Cell Immunomodulator (LTCI) for Canine Osteoarthritis
Canine B-Cell Lymphoma
Canine T-Cell Lymphoma
Tumor-derived Immunotherapy for cancer (canine)
Immunotherapeutic for the treatment of mixed mammary tumor and mammary adenocarcinoma in dogs.